Open AccessEffectiveness and safety of Liuhedan for treating acute pancreatitis
Author(s) -
Tao Cheng,
Bofu Liu,
Tian-Yong Han,
Zhi-Han Gu,
Pan Pan,
Honggang Yu
Publication year - 2021
Publication title -
medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.59
H-Index - 148
eISSN - 1536-5964
pISSN - 0025-7974
DOI - 10.1097/md.0000000000024863
Subject(s) - medicine , acute pancreatitis , pancreatitis , intensive care medicine , medline , political science , law
Background: Liuhedan is a famous traditional Chinese medicine (TCM) formula used to treat acute pancreatitis (AP) in China. However, there is no systematic reviews for the evidence and the therapeutic effectiveness and safety of Liuhedan for treating AP. The aim of this study is to summarize previous evidence, assessing the efficacy and safety of Liuhedan in the treatment of AP. Methods: We will search the EMBASE, WANFANG DATA, Web of Knowledge, CNKI, PubMed, ClinicalTrials.gov and Cochrane Library from inception to June 30, 2021 to retrieve relevant studies using the search strategy: (“Liuhedan” OR “Liuhe Pill” OR “Liu-He-Dan”) AND (“pancreatitis” OR “pancreatitides”). Two authors independently judged study eligibility and extracted data. Heterogeneity will be examined by computing the Q statistic and I 2 statistic. Results: This study assessed the efficiency and safety of Liuhedan for treating acute pancreatitis. Conclusions: This study will provide reliable evidence-based evidence for the clinical application of Liuhedan for treating AP. Ethics and dissemination: Ethical approval is unnecessary as this protocol is only for systematic review and does not involve privacy data. The findings of this study will be disseminated electronically through a peer-review publication or presented at a relevant conference.